Roche acquires Lumora’s heat elution technology
Lumora, a provider of state-of-the-art molecular diagnostic products for the clinical research and industrial markets, has sold its proprietary nucleic acid heat elution purification technology to Roche. Roche has signed a definitive asset purchase agreement with Lumora for products associated with its proprietary nucleic acid heat elution purification technology that is designed for use with clinical specimens.
Roche plans to explore integrating this technology into its sequencing workflow solution. Financial details were not disclosed.
Today, nucleic acid purification technology from specimens including formalin-fixed tissues is cumbersome and inefficient. Lumora’s highly differentiated proprietary methodology is designed to enable simple and automated nucleic acid isolation in minutes instead of hours. In addition, the technology is environmentally friendly and can be applied to process a wide variety of samples including whole blood, faecal matter, sputum and buccal swabs.
Lumora’s heat elution purification technology is for research use only, not for use in diagnostic procedures.